This open-label, phase 2a trial enrolled patients with genotype 1 HCV who previously had failed a 24-week course of sofosbuvir plus ribavirin and retreated them using fixed-dose combination of ledipasvir-sofosbuvir for 12 weeks. A total of 14 patients enrolled and all had prior relapse as the cause of treatment failure.  Among the 14 patients, 13 were male and 13 were black.  One half of those enrolled had advanced fibrosis (Knodell Histology Activity Index score of 3 or 4). The virologic response rates were excellent, with 14 (100%) of 14 patients achieving an SVR12. This small study is very promising but should be confirmed by larger future studies, which could include prior nonresponders.